Publications

• Maier S, Nimmrich I, Koenig T, Eppenberger-Castori S, Bohlmann I, Paradiso A, Spyratos F, Thomssen C, Mueller V, Nährig J, Schittulli F, Kates R, Lesche R, Schwope I, Kluth A, Marx A, Martens JW, Foekens JA, Schmitt M, Harbeck N: DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients - Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group. Eur J Cancer. 2007 Jun 28
• Vuaroqueaux V, Urban P, Labuhn M, Delorenzi M, Wirapati P, Benz CC, Flury R, Dieterich H, Spyratos F, Eppenberger U and Eppenberger-Castori S:
  Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome. Breast Cancer Res. 2007 May 29, 9:R33
• Tommasi S, Fedele V, Lacalamita R, Bruno M, Schittulli F, Ginzinger D, Scott G, Eppenberger-Castori S, Calistri D, Casadei S, Seymour I, Longo S, Giannelli G, Pilato B, Simone G, Benz CC, Paradiso A:
  655Val and 1170Pro ERBB2 SNPs in familial breast cancer risk and BRCA1 alterations. Cell Oncol. 2007;29(3):241-8
• Zhou Y, Yau C, Gray JW, Chew K, Dairkee SH, Moore DH, Eppenberger U, Eppenberger-Castori S, Benz CC:
  Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer.BMC Cancer. 2007 Apr 3;7:59

2006

• Urban P, Vuaroqueaux V, Labuhn M, Wight E, Benz C, Senn H-J, Eppenberger U, Eppenberger-Castori S:
  Increased expression of urokinase-type plasminogen activator (uPA) mRNA determines adverse prognosis in ErbB2-positive breast cencer patients. J Clin Oncol. 2006 Sep 10;24(26):4245-53. 2006
• Zanetti-Dällenbach R, Vuaroqueaux V, Wight E, Labuhn M, Singer G, Urban P, Eppenberger U, Holzgreve W, Eppenberger-Castori S:
  Comparison of gene expression profiles in core biopsies and corresponding surgical breast cancer samples. Breast Cancer Res. 2006 Aug 18;8(4):R51
• Benz CC, Fedele V, Xu F, Ylstra B, Ginzinger D, Yu M, Moore D, Hall RK, Wolff DJ, Disis ML, Eppenberger-Castori S, Eppenberger U, Schittulli F, Tommasi S, Paradiso A, Scott GK, Albertson DG:
  Altered promoter usage characterizes monoallelic transcription arising with ERBB2 amplification in human breast cancers Genes Chromosomes and Cancer. 2006 Aug 1
• 22. Labuhn M, Vuaroqueaux V, Fina F, Schaller A, Nanni-Metellus I, Kung W, Eppenberger-Castori S, Martin PM, Eppenberger U:
  Simultaneous quantitative detection of relevant biomarkers in breast cancer by quantitative real-time PCR. Int J Biol Markers. 2006 Jan-Mar;21(1):30-9.
• 21. Breuleux M, Schoumacher F, Rehn D, Kung W, Mueller H, Eppenberger U:
  Heregulins implicated in cellular functions other than receptor activation. Mol Cancer Res. 2006 Jan;4(1):27-37.
• 20. Cicenas J, Urban P, Kung W, Vuaroqueaux V, Labuhn M, Wight E, Eppenberger U, Eppenberger-Castori S:
  Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients. Eur J Cancer. 2006 Mar;42(5):636-45. Epub 2006 Jan 18.
• 19. Weissenstein U, Schneider MJ, Pawlak M, Cicenas J, Eppenberger-Castori S, Oroszlan P, Ehret S, Geurts-Moespot A, Sweep FC, Eppenberger U:
  Multiplexed Protein Chip Based Assay for Simultaneous Quantitative Monitoring of Cancer Biomarkers in Tissue Extracts. Proteomics. 2006 Mar;6(5):1427-36.

2005

• Cicenas J, Urban J, Kung W, Vuaroqueaux V, Labuhn M, Wight E, Eppenberger U, Eppenberger-Castori S:
  Increased levels of phosphorylated akt measured by chemiluminescence-linked immunosorbert assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2, Breast Cancer Res. 2005; 7 (3): R394-R401.
• 17. Zhou Y, Eppenberger-Castori S, Eppenberger U, Benz CC:
  The NFkappaB pathway and endocrine-resistant breast cancer. Endocr Relat Cancer 2005 12 Suppl 1 S37-46
• 16. Zhou YA, Eppenberger-Castori S, et al:
  Activation of nuclear factor-kappaB (NFkappaB) identifies a high-risk subset of hormone-dependent breast cancers. Int J Biochem Cell Biol. 2005 May;37(5):1130-44.

2000-2004

• Hornung R, Eppenberger U, Eppenberger-Castori S. et al:
  Analysis of potential prognostic factors in 111 patients with ovarian cancer. 1: Cancer Lett. 2004 Mar 31;206(1):97-106.
• Look M, van Putten W, … Eppenberger-Castori S, Sweep FCG, Ulm K, Peyrat JP, Martin PM, Magdelenat H, …Eppenberger U, Janicke F, Schmitt M, Foekens J:
  Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients. Thromb Haemost. 2003 Sep;90(3):538-48.
• Benz CC, Thor AD, Eppenberger-Castori S, Eppenberger U, Moore D:
  3rd. Understanding the age dependency of breast cancer biomarkers. Adv Gerontol. 2003;11:117-20. Review.
• Quong J, Eppenberger-Castori S, Moore D, Scott GK, Birrer MJ, Kueng W, Eppenberger U, and Benz CC:
  Age-dependent changes in breast cancer hormone receptors and oxidant stress markers. Breast Cancer Res. Treat., 76: 221-236, 2002.
• Eppenberger-Castori S, Moore D, Thor A, Edgerton S, Kueng W, Eppenberger U, Benz C:
  Age-associated biomarker profiles of human breast cancer. Int J Biochem Cell Biol 34 (11): 1318, 2002.
• Look MP, van Putten WLJ, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C,..., Eppenberger-Castori S, Eppenberger U, Jänicke F, Schmitt M,Foekens JA:
  Prognostic impact of plasminogen activator components in breast cancer: a meta-analysis. J Nat Canc Inst, 94(2):116-28, 2002.
• Serenella Eppenberger-Castori, Willy Kueng, et al:
  Prognostic and Predictive Significance of ErbB-2 Breast Tumor Levels Measured by Enzyme-Immuno-Assay (EIA), J Clin Oncol 19:645-656, 2001
• Eppenberger U, Levano S, Evans D, Schoumacher F, Müller H and Eppenberger-Castori S:
  Molecular epidemiology of aromatase expression in 1182 primary breast cancers in aromatase inhibition and breast cancer ed. W. R. Miller & R. J. Santen. Marcel Dekker, Inc. New York, 2000
• Müller H, Flury N, Eppenberger-Castori S, Küng W, David F and Eppenberger U:
  Potential prognostic value of mitogen-activated protein kinase activity for desease-free survival of primary breast cancer patients. Int J Cancer 89: 384-388, 2000
• Quong, Eppenberger-Castori S, Birrer M, Eppenberger U and Benz CC:
  Redox-sensitive kinase (erk5) activation and altered transcription factor (ap-1. Sp1) dna binding in untreated primary breast tumors. ACCR, 2000

Vor 2000

• Eppenberger U, Kueng W, Schlaeppi JM, .. Eppenberger-Castori S:
  Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients. J Clin Oncol 16:3129-36, 1998
• Gallacchi P, Schoumacher F, Eppenberger-Castori S, et al:
  Increased expression of estrogen-receptor exon-5-deletion variant in relapse tissues of human breast cancer. Int J Cancer 79:44-8, 1998
• Eppenberger U, Kueng W, Eppenberger-Castori S, et al:
  [Molecular factors determine primary and secondary therapy of breast carcinoma]. Ther. Umsch. 54:451-6, 1997
• Garvin AM, Eppenberger U, Muller H, Eppenberger-Castori S, et al:
  BRCA1 mutations found in archived early onset breast tumours. Eur J Cancer 33:683-6, 1997
• Garvin AM, Mueller H, Eppenberger-Castori S, et al:
  Informed consent and BRCA1 mutation detection in archived breast tumor specimens [letter]. Lancet 347:1189, 1996

Tissue Biobank Basel

Institute for Pathology | Schoenbeinstrasse 40 | CH-4003 Basel | Switzerland | Phone +41 61 328 6820 | Fax +41 61 265 2966 | sere.eppenberger@unibas.ch